Trials / Recruiting
RecruitingNCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Rita Assi · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Conditions
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- B-cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATRA | 150 mg/m2 ATRA orally for 3 days surrounding each of the first four cycles (day -1, day 0, day +1) |
| DRUG | Pembrolizumab | 200mg Q3W pembrolizumab |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2027-12-01
- Completion
- 2029-09-01
- First posted
- 2024-07-03
- Last updated
- 2026-02-10
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06484920. Inclusion in this directory is not an endorsement.